Investigation of the treatment potential of Raloxifene-loaded polymeric nanoparticles in osteoporosis: In-vitro and in-vivo analyses

Investigation of the treatment potential of Raloxifene-loaded polymeric nanoparticles in osteoporosis: In-vitro and in-vivo analyses

Blog Article

Osteoporosis (OP), is a systemic bone disorder associated with low bone mass and bone tissue corrosion.Worsening of the disease condition leads to bone delicacy Mountaineering - Femme - Chaussures and fracture.Various drugs are available for the treatment of OP, however they have limitations including poor solubility, bioavailability and toxicity.Herein, Raloxifene-loaded polymeric nanoparticles (RLX-PNPs) were developed and investigated for the treatment of OP with possible solutions to the above mentioned problems.RLX-PNPs were prepared by modified ionic gelation method followed by determining their particle properties.

FTIR, DSC and PXRD analysis of the RLX-PNPs were performed to check chemical interaction, thermal behavior and crystallinity, respectively.In-vitro release profile of RLX-PNPs was checked in lab setting, whereas its pharmacokinetics was investigated in Sprague-Dawley rats, in-vivo.Finally, the treatment potential of RLX-PNPs was analyzed in OP induced animal model.The optimized PNPs formulation indicated 134.5 nm particle size, +24.

4 mV charge and 91.73% % EE.TEM analysis showed spherical and uniform sized particles with no interactions observed in FTIR analysis.In-vitro release of RLX from RLX-PNPs showed more sustained release behavior as compared to RLX-suspension.Moreover, pharmacokinetic investigations showed a significantly enhanced bioavailability of the RLX-PNPs as well as reduced serum levels of alkaline phosphatase and calcium in OP Charging Pad induced rats when compared with RLX-Suspension after oral administration.

Findings of this study suggested that the developed RLX-PNPs have the potential to treat OP due to sustained release and improved bioavailability of the incorporated drug.